Hepatocellular carcinoma remains a global health challenge affecting close to 1 million
cases yearly. Liver transplantation provides the best long‐term outcomes for those meeting …

Simple Summary Hepatocellular carcinoma (HCC) is the most common type of liver cancer,
accounting for approximately 85–90% of all cases of liver cancer worldwide. The five-year …

Background Combined treatment with tyrosine kinase inhibitors (TKI) plus anti-PD-1
antibodies showed high anti-tumor efficacy and made conversion resection possible for …

Purpose Conversion therapy gives some patients with initially unresectable hepatocellular
carcinoma (HCC) access to surgery. The purpose of this study was to evaluate the safety …

Hepatocellular carcinoma (HCC) has been the fifth most common malignancy worldwide
and is the second most common cause of tumor-related mortality globally. In China, a high …

Background Over 70% of the patients with hepatocellular carcinoma (HCC) are diagnosed
at an advanced stage and lose the opportunity for radical surgery. Combination therapy of …

Purpose In recent years, immune checkpoint inhibitors have been used in combination with
tyrosine kinase inhibitors and local therapies, creating a new era in treating hepatocellular …

Hepatocellular carcinoma (HCC) is a malignancy that requires multidisciplinary evaluation
to develop individualized and tailored treatment concepts. While liver resection and …

Background To assess the perioperative safety, oncological outcomes, and determinants
influencing the oncological outcomes of salvage liver resection for initially unresectable …

Aim To understand the proportion of uHCC (unresectable hepatocellular carcinoma)
patients who achieve successful conversion resection in a high-volume setting with state of …